Although asthma, a disease for which no known preventive strategies exist, has a strong hereditary basis, disease risk is likely modified by environmental and early-life exposures. One such early-life exposure, infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), has a strong association with asthma. [1] [2] [3] Infant RSV LRTI precedes asthma and is associated with a severity-dependent odds of asthma. 3 Furthermore, risk of asthma has been linked with birth timing in relationship to respiratory virus circulation, 2 and animal studies demonstrate biologic mechanisms through which RSV LRTI could contribute to asthma development. [4] [5] [6] [7] [8] Both observational studies and a recent randomized controlled trial (RCT) demonstrate that preventing RSV LRTI decreases recurrent wheezing and 1-year wheezing outcomes, respectively. [8] [9] [10] [11] Determining whether prevention of infant RSV LRTI prevents asthma is important because the ability to modify the risk of a lifelong chronic disease has remained elusive.
RSV immunoprophylaxis administered during the RSV season to high-risk infants is efficacious in the prevention of RSV hospitalization, and the American Academy of Pediatrics (AAP) has issued recommendations for its use in infants at high risk for severe RSV. [12] [13] [14] [15] [16] [17] [18] [19] [20] To address the question of whether prevention of severe infant RSV decreases the risk of early childhood asthma, we took advantage of the known high risk of severe RSV and asthma among groups for whom immunoprophylaxis is recommended. 12, 21, 22 The use of observational methods to study whether RSV immunoprophylaxis decreases asthma in high-risk infants allows estimation of effect size in this select population within a real-world context. However, confounding by indication is important: among patients eligible for immunoprophylaxis, infants with the highest risk of subsequent asthma are more likely to receive immunoprophylaxis. 23 Thus the drug will appear to be associated with increased disease risk, probably because of residual confounding related to medical complexity. In this report we describe how we tested the hypothesis that increased adherence to RSV immunoprophylaxis would be associated with a decreased odds of asthma at age 4.5 to 6 years.
METHODS

Study design
This study was approved by the Institutional Review Boards of Kaiser Permanente Northern California (KPNC), the State of California Committee for the Protection of Human Subjects, and Vanderbilt University Medical Center and representatives of the Tennessee Department of Health and the Bureau of TennCare. 23 We conducted a retrospective cohort investigation of children enrolled in the Prevention of RSV: Impact on Morbidity and Asthma (PRIMA) cohort who were at increased risk for severe RSV and eligible to receive RSV immunoprophylaxis during infancy. The PRIMA cohort is composed of 2 large population-based birth cohorts followed through age 6 years from KPNC and Tennessee Medicaid (TennCare). 23 This investigation of receipt of RSV immunoprophylaxis during infancy and early childhood asthma included infants born between January 1, 1996, and December 31, 2003, to allow adequate follow-up time to age 6 years. 23 For KPNC, data were obtained from linked administrative and clinical databases, the electronic medical record, and California vital records files, as previously described. 23 In 1994, TennCare replaced the federal Medicaid program as a state-based managed health care program that covered Medicaid-eligible subjects and the uninsured; approximately 50% of infants in Tennessee are covered by TennCare. 3, 23, 24 For the TennCare population, all data were obtained from linked TennCare administrative files and Tennessee vital records files, as previously described. 23, [25] [26] [27] Eligibility to receive RSV immunoprophylaxis Children eligible for study inclusion were continuously enrolled in either KPNC or TennCare during their first year and between the ages of 4.5 and 6 years. Continuous enrollment was defined as no more than 90 days of nonenrollment during the first year of life and no more than 60 days of nonenrollment between the ages of 4.5 and 6 years. 23 Eligibility for receipt of RSV immunoprophylaxis was determined according to AAP recommendations in place during the study period (see the Methods section in this article's Online Repository at www.jacionline.org). 16, 18, 19 As previously described, eligible children were classified into 4 hierarchical, mutually exclusive groups: (1) Chronic lung disease (CLD) was defined as CLD with prescriptions filled for CLD medication within 6 months of RSV season; (2) Prematurity <29 was defined as estimated gestational age (EGA) of less than 29 weeks; (3) Prematurity <32 was defined as EGA of less 32 weeks; and (4) Other eligible was defined as 32 to less than 35 weeks of EGA and less than 6 months of age at the RSV season with both maternal smoking and an older sibling or International Classification of Diseases, Ninth Revision (ICD-9), diagnoses of cyanotic or hemodynamically significant congenital heart disease, neurologic condition, or congenital anomaly of airway. 16, 23, 28 The start of the RSV season was defined as November 1. Children with CLD who did not require medication were categorized by EGA.
Main predictor: Percentage adherence to RSV immunoprophylaxis during infancy
During the study period, the AAP recommended that eligible children receive monthly injections throughout the RSV season, typically November to March. We identified all RSV immunoprophylaxis encounters throughout the study period. 23 We calculated the recommended number of doses each infant should have received based on their eligibility group, birth date, and month of hospital discharge in relation to RSV season. 23 We calculated the percentage receipt of recommended doses (adherence) by dividing the number of doses received by the number of recommended doses and used this value as continuous or categorized for comparison of different levels of adherence by type of analysis. 23 
Outcome of early childhood asthma
We determined diagnoses of asthma between 4.5 and 6 years of age to allow a window for diagnosis and to exclude potential ''transient early wheezers.'' 3, 29 We defined asthma using a validated algorithm that incorporates asthma-specific health care encounters and medication claims by using a modified Healthcare Effectiveness Data and Information Set definition. 3, 30, 31 Children with an asthma-specific ICD-9 code (493) from a hospitalization, 23-hour observation, or emergency department visit or 2 or more clinic visits were classified as having asthma. In addition, children with 2 or more prescription fills for a short-acting b-agonist within a 12-month period or a prescription fill for other asthma medications (including inhaled corticosteroids and long-acting b-agonists) were classified as having asthma.
Covariates
We used administrative data linked with vital records to identify covariates. Birth certificate data were used to determine infant characteristics (sex, EGA, and birth weight) and maternal demographics and characteristics (race, education, smoking status during pregnancy, gravidity status, and number of previous live births). Small for gestational age (SGA) (<5th percentile) status was determined by using standard methods. 32 Infant birth hospitalization length of stay (LOS) and health care visits for bronchiolitis were identified by using administrative data. 23 
Statistical analyses
The main outcome variable was asthma, which was defined as a dichotomous variable (asthma present vs no) ascertained between 4.5 and 6 years of age. We have demonstrated that prematurity and SGA are associated with higher adherence to RSV immunoprophylaxis in this cohort, 23 and thus a priori, we decided to use different multivariable adjustment approaches to address confounding. Therefore in addition to conventional multivariable logistic regression, we used propensity score (PS) methods to perform PS-adjusted and PS-matched analyses (see the Methods section and Fig E1 in this article's Online Repository at www.jacionline.org). In univariate analysis we compared the proportion of children with asthma by categories defining the degree of adherence using Pearson x 2 statistics. Continuity corrections were not used for 2 3 2 tables. RSV immunoprophylaxis predictor categories were specified by the type of multivariable analyses conducted. For the multivariable and PS-adjusted analyses, we defined the degree of adherence as no receipt, less than 70% adherence, and 70% adherence or greater. For PS-matched analyses, the subset of children with extremes of RSV immunoprophylaxis adherence were included (see the Methods section in this article's Online Repository). 33 Covariates in the multivariable models included infant sex, EGA, EGA plus birth hospital LOS, birth weight, bronchiolitis diagnosis, season of birth (RSV season: October-March vs non-RSV season: April-September), birth year, number of living siblings, maternal race, age, education, gravidity, smoking during pregnancy, and site. For TennCare, when birth hospital LOS was missing, it was imputed, as previously described. 23 Each regression adjustment method (multivariable logistic regression and PS-adjusted and PS-matched models) was conducted in the all RSV immunoprophylaxis-eligible cohort and in each subgroup based on eligibility criteria (CLD, Prematurity <29, Prematurity <32, and Other eligible). Adjusted odds ratios (ORs) for asthma were determined by means of adherence to AAP RSV immunoprophylaxis recommendations, which were categorized as no receipt, less than 70% adherence, or 70% or greater adherence in the conventional multivariable and PS-adjusted models. Model fits (for conventional logistic regression methods) were assessed by using the goodness-of-fit test (Cessie-van Houwelingen-Copas-Hosmer), and there was no statistically significant evidence of lack of fit in our logistic regression models.
PS adjustment models. PS was derived by using a proportional odds ordinal logistic regression model for treatment (RSV immunoprophylaxis) with 3 level categories (no receipt, <70% adherence, and > _70% adherence) and included as a covariate in the PS adjustment models. 34 After derivation of the PS, in adjustment models restricted cubic splines were used to allow for nonlinear adjustment between PS and outcome.
PS-matched treatment groups. We derived the PS for matched analyses by using binary logistic regression with high and low ends of receipt, including 70% or greater adherence and greater than 0% to 20% or less adherence. 23 The PS-matched model included 1:1 matching with replacement 33, 35 based on the PS to assess the association of percentage adherence with the recommended number of doses of RSV immunoprophylaxis in infancy and subsequent asthma. In the matched analysis conditional logistic regression and robust SE estimates were used to account for the clustered data. The significance level for all analyses was a P value of less than .05.
To assess the effect of missing covariate data, we conducted conventional multivariable adjustment models by using multiple imputation of missing variables. Because the results of these analyses remained unchanged, we present complete case analyses. Overall, less than 2% of children were excluded from multivariable analyses because of missing/unknown data. Analyses were conducted with SAS (version 9.1; SAS Institute, Cary, NC) and R (version 3.0.1; http://www.r-project.org) software.
34-36
RESULTS
A total of 6571 children eligible to receive RSV immunoprophylaxis were included (Table I ). The percentages of children in the RSV immunoprophylaxis eligibility groups were as follows: 10% in the CLD group, 33% in the less than 29-week EGA group, 48% in the 29-to less than 32-week EGA group, and 9% in the other eligibility group (9%). Asthma prevalence at age 4.5 to 6 years varied according to eligibility group, affecting 45%, 23%, 19%, and 17% in the CLD, less than 29-week EGA, 29-to less than 32-week EGA, and other eligibility groups, respectively. Overall, the majority of infants received at least 1 dose of RSV immunoprophylaxis, which was categorized as no receipt (36%), less than 70% adherence (30%), and 70% or greater adherence (34%). There were notable differences between eligible infants who did and did not receive immunoprophylaxis (Table I ). Although the group that did not receive RSV immunoprophylaxis and those with 70% or greater adherence had a similar EGA (30 vs 29 weeks, respectively), substantial bias was evident. Compared with the group that did not receive RSV immunoprophylaxis, infants with 70% or greater adherence were more likely to have CLD (45% vs 22%), have lower median birth weight (1179 vs 1510 grams), be SGA (8% vs 4%), and have longer median birth hospital LOS (50 vs 31 days). Table II shows that 23% of children eligible for RSV immunoprophylaxis were given a diagnosis of asthma between 4.5 and 6 years of age, including 19%, 22%, and 28% in the no receipt, less than 70% adherence, and 70% or greater adherence groups, respectively. In the multivariable and PS-adjusted regression models of the combined group, statistically significant differences in the relative odds of asthma were not detected in the most adherent group (> _70%) or those with less than 70% adherence (Table II) compared with children with no receipt. In the PS-matched model that compared children who received 70% or greater of the recommended doses with those who received at least 1 dose but were 20% or less adherent, a decreased odds of early childhood asthma was detected (0.62 [0.50-0.78], Table III) .
We also investigated adherence to RSV immunoprophylaxis and childhood asthma by eligibility group. For children in the CLD group, 45% of the 651 children were given a diagnosis of asthma between 4.5 and 6 years of age, including 36%, 42%, and 51% in the no receipt, less than 70% adherence, and 70% or greater adherence groups, respectively. In comparison with the group that did not receive RSV immunoprophylaxis, children in the less than 70% or 70% or greater adherence groups did not have a statistically significant difference in relative odds of early childhood asthma in the multivariable or PS-adjusted models (Table II ). An increased odds of early childhood asthma was detected in the PS-matched model (adjusted OR, 1.76; 95% CI, 1.41-2.20; Table III) . Additionally, separate multivariable and PS-adjusted analyses were conducted for children in the less than 29-week EGA, 29-to less than 32-week EGA, and other eligible groups; however, statistically significant differences were not detected in the relative odds of early childhood asthma by percentage adherence to RSV immunoprophylaxis (Table II) . In contrast, in a PS-matched analysis that compared children in the 70% or greater adherence group with those in the 20% or less adherence group (of children who received > _1 dose), a decreased odds of early childhood asthma was detected in the less than 29-week EGA group (adjusted OR, 0.36; 95% CI, 0.13-0.97) and the 29-to less than 32-week EGA group (adjusted OR, 0.63; 95% CI, 0.42-0.93; Table III) .
DISCUSSION
Viral LRTIs during infancy are associated with increased asthma risk in childhood, representing a potentially modifiable risk factor. 2, 37, 38 Observational studies designed to test whether therapeutic agents that are efficacious in preventing severe RSV can prevent asthma are plagued by the problem of confounding by indication and medical risk. Within our risk categories, there was a spectrum of illness severity, with those at higher risk more likely to receive RSV immunoprophylaxis and also have higher adherence, whereas infants with lower adherence or nonadherence were healthier. In the multivariable and PS-adjusted models greater adherence to RSV immunoprophylaxis was not associated with decreased asthma later in life. In the analyses of the subcohort with matching by PS design, we detected a protective effect in the combined eligibility and prematurity groups, although an increased odds was found in the CLD group. Although PS matching limits sample size and relies on appropriate and available data, it provides the best balance between treatment groups.
Several findings in the previous literature led us to investigate whether increased adherence to RSV immunoprophylaxis recommendations would be associated with decreased odds of subsequent asthma. Multiple independent cohorts have demonstrated that children with RSV-induced bronchiolitis during infancy have an increased relative odds of early childhood [37] [38] [39] and our group has demonstrated a severitydependent association. 3 In addition, we have found that birth in relationship to winter virus season is associated with subsequent asthma risk, 2 a finding that suggests that exposure to viruses during susceptible periods in early life might play a causal role in asthma inception. Previous research findings have demonstrated efficacy of RSV immunoprophylaxis in decreasing the risk of RSV-related hospitalization, 14, 15 and in an RCT of infants born at EGA of 33 to 35 weeks, Blanken et al 11 found that RSV immunoprophylaxis was associated with decreased wheezing days, including the postprophylaxis period, and decreased recurrent wheezing in the first year of life. 11 Importantly, recent animal studies provide insights into the biologic mechanisms through which RSV could cause asthma. [5] [6] [7] It is important to note that for the most high-risk infants, such as infants with CLD, extreme prematurity, or both, with currently available knowledge, our research question can only be addressed by using an observational study design because it can be considered unethical in certain countries to conduct an RCT of RSV immunoprophylaxis among infants for whom RSV immunoprophylaxis is recommended. Although the most recent AAP guidelines, which were not in place during our study period, recommend RSV immunoprophylaxis in fewer children, recommendations for use remain in place for children with CLD, extreme prematurity, or both, although in our study we were not able to capture CLD, as defined in the current guidelines. 40 As found in the current study, groups with the highest risk for severe RSV also have the highest prevalence of asthma during childhood, reaching 45% in the CLD group. Therefore even given the narrowing of the scope of recommendations for RSV immunoprophylaxis and the policy statement that RSV immunoprophylaxis should not be used for asthma prevention, investigations using observational study designs to assess the association of adherence to asthma development have the potential to provide important insights into whether a currently used therapeutic agent is associated with a decrease in the burden of a potentially lifelong chronic disease in a relevant and disproportionately affected subset of children for whom receipt is recommended.
Findings in our multivariable and PS-adjusted models did not demonstrate that RSV immunoprophylaxis decreased asthma odds. Although we used a set of statistical adjustment strategies to address differences between comparison groups, it is possible that we were not able to control for important confounders that influenced adherence and imbalance in prognostically important variables. In addition, although this KPNC-TennCare collaboration provided the largest retrospective cohort study to date that addressed our primary research question, a larger sample size might have enhanced our ability to overcome confounding bias, particularly in the subgroups with smaller numbers. In an attempt to reduce substantial indication bias, PS matching with replacement was used, limiting sample size; for example, in the CLD subgroup we had 90 subjects with greater than 0% but 20% or less adherence and 324 with 70% or greater adherence. This might have contributed to the inconsistent results. We were not able to quantify the extent to which sample size affected the results. 33, 41 In our analyses with PS matching, we detected a protective effect of immunoprophylaxis on asthma in the combined eligibility group and the 2 prematurity groups, although an increased odds was found in the CLD group. Because the underlying pulmonary architecture and physiology differ between children with and without CLD, it is biologically plausible that prevention of RSV would prevent subsequent pathologic airway changes or host responses in children without chronic lung pathology or with milder disease but not alter the course of asthma development in children with the most severe CLD.
There are several limitations of this retrospective cohort study. We categorized infants into RSV immunoprophylaxis eligibility groups using administrative data, and we were not able to identify all risk factors used to determine eligibility for infants born between 32 and 35 weeks of EGA. In addition, there were likely unmeasured factors related to neonatal course severity that influenced which children received immunoprophylaxis. We defined asthma outcomes by using ICD-9 diagnoses and medication use, and this might not detect asymptomatic subjects or those without a diagnosis. Although our method of detecting asthma is similar to a definition found to be sensitive and specific for persistent asthma, it is possible that this definition captures diverse wheezing phenotypes. 30, 31 The strengths of our study include a large population of children recruited from a managed care plan, as well as a state Medicaid health care plan, and objective information on administration of RSV immunoprophylaxis and asthma diagnosis.
In summary, we investigated the association of adherence to RSV immunoprophylaxis during infancy and asthma diagnosis at 4.5 to 6 years of age. Using standard statistical adjustment methods, our results suggest that we were unable to overcome confounding by indication, with the highest-risk children having the highest adherence to RSV prophylaxis. For example, we found increased asthma in children with CLD who were most adherent to RSV immunoprophylaxis, but these infants also had the most severe neonatal course, the highest prevalence of RSV LRTI, and the highest prevalence of asthma. The results obtained in PS-matched analysis in preterm infants provide insight into what the protective effect size might be across gestational ages to inform future prospective and intervention studies. Our findings support the need for larger studies to overcome potential sample size limitations, prospective cohorts with more precise measurement of exposure data, continued method development to overcome bias in observational data, and long-term follow-up of respiratory outcomes in ongoing vaccine trials should these vaccines prove to be effective. We thank the Tennessee Bureau of TennCare of the Department of Financed Using a priori-defined statistical adjustment strategies in efforts to control for confounding by medical complexity in an observational study of high-risk infants, higher adherence to RSV immunoprophylaxis was not associated with decreased odds of asthma in the combined group of eligible children by using standard multivariable and PSadjusted models.
METHODS
Study design
This study was approved by the Institutional Review Boards of KPNC, the State of California Committee for the Protection of Human Subjects, and Vanderbilt University Medical Center and representatives of the Tennessee Department of Health and the Bureau of TennCare. E1 We conducted a retrospective cohort investigation of children enrolled in the PRIMA cohort who were at increased risk for severe RSV and eligible to receive RSV immunoprophylaxis during infancy. The PRIMA cohort is composed of 2 large population-based birth cohorts followed through age 6 years from KPNC and Tennessee Medicaid (TennCare). E1 This investigation of receipt of RSV immunoprophylaxis during infancy and early childhood asthma included infants born between January 1, 1996, and December 31, 2003, to allow adequate follow-up time to age 6 years.
E1 For KPNC, data were obtained from linked administrative and clinical databases, the electronic medical record, and California vital records files, as previously described. E1 In 1994, TennCare replaced the federal Medicaid program as a state-based managed health care program that covered Medicaid-eligible subjects and the uninsured; approximately 50% of infants in Tennessee are covered by TennCare.
E1-E3 For the TennCare population, all data were obtained from linked TennCare administrative files and Tennessee vital records files, as previously described.
E1,E4-E6
Eligibility to receive RSV immunoprophylaxis
Children eligible for study inclusion were continuously enrolled in either KPNC or TennCare during their first year and between ages 4.5 and 6 years. Continuous enrollment was defined as no more than 90 days of nonenrollment during the first year of life and no more than 60 days of nonenrollment between 4.5 and 6 years of age.
E1 Eligibility for receipt of RSV immunoprophylaxis was determined according to AAP recommendations in place during the study period, E7-E9 including (1) infants less than 2 years of age with CLD who required medical therapy within 6 months of RSV season, (2) infants born at 28 weeks of EGA during their first RSV season, (3) infants born at 29 to 32 weeks of EGA and particularly less than 6 months of age at the start of the RSV season, and (4) infants who were born between 32 and 35 weeks of EGA, were less than 6 months old at the start of RSV season, and had 2 or more risk factors (attended child care, had school-aged siblings, had exposure to environmental air pollutants, had congenital abnormalities of the airways, or had severe neuromuscular disease).
E7,E8 As previously described, for this current study, eligible children were classified into 4 hierarchical, mutually exclusive groups: (1) CLD was defined as CLD with prescription filled for CLD medication within 6 months of RSV season; (2) Prematurity <29 was defined as EGA of less than 29 weeks; (3) Prematurity <32 was defined as EGA of <32 weeks; and (4) Other eligible was defined as 32 to less than 35 weeks of EGA and less than 6 months of age at RSV season with both maternal smoking and an older sibling or ICD-9 diagnoses of cyanotic or hemodynamically significant congenital heart disease, neurologic condition, or congenital anomaly of airway.
E1,E7,E10 The start of the RSV season was defined as November 1. Children with CLD who did not require medication were categorized by EGA.
Main predictor: Percentage adherence to RSV immunoprophylaxis during infancy
During the study period, the AAP recommended that eligible children receive monthly injections throughout the RSV season, typically November to March. We identified all RSV immunoprophylaxis encounters throughout the study period. E1 We calculated the recommended number of doses each infant should have received based on their eligibility group, birth date, and month of hospital discharge in relation to RSV season. E1 We calculated the percentage receipt of recommended doses (adherence) by dividing the number of doses received by the number of recommended doses and used this value as continuous or categorized for comparison of different levels of adherence by type of analysis.
E1
Outcome of early childhood asthma
We determined diagnoses of asthma between 4.5 and 6 years of age to allow a window for diagnosis and to exclude potential ''transient early wheezers.'' E3,E11 We defined asthma by using a validated algorithm that incorporates asthma-specific health care encounters and medication claims by using a modified Healthcare Effectiveness Data and Information Set definition.
E3,E12,E13 Children with an asthma-specific ICD-9 code (493) from a hospitalization, 23-hour observation, or emergency department visit or 2 or more clinic visits were classified as having asthma. In addition, children with 2 or more prescription fills for a short-acting b-agonist within a 12-month period or a prescription fill for other asthma medications (including inhaled corticosteroids and long-acting b-agonists) were classified as having asthma.
Covariates
We used administrative data linked with vital records to identify covariates. Birth certificate data were used to determine infant characteristics (sex, EGA, and birth weight) and maternal demographics and characteristics (race, education, smoking status during pregnancy, gravidity status, and number of previous live births). SGA (<5th percentile) was determined by using standard methods. E14 Infant birth hospitalization LOS and health care visits for bronchiolitis were identified by using administrative data.
E1
Statistical analyses
The main outcome variable was asthma, which was defined as a dichotomous variable (asthma present vs no) ascertained between 4.5 and 6 years of age. We have demonstrated that prematurity and SGA are associated with higher adherence to RSV immunoprophylaxis in this cohort, E1 and thus a priori, we decided to use different multivariable adjustment approaches to address confounding. Therefore in addition to conventional multivariable logistic regression, we used PS methods to perform PS-adjusted and PS-matched analyses. We examined the association between asthma outcome and the adherence predictor included as a flexible smooth parameter by using cubic spline regression (2 df with 3 knots) in multivariable analyses and did not detect nonlinearity (see Fig E1) . In univariate analysis we compared the proportion of children with asthma by categories defining the degree of adherence using Pearson x 2 statistics. RSV immunoprophylaxis predictor categories were specified by the type of multivariable analyses conducted. For the multivariable and PS-adjusted analyses, we defined the degree of adherence as no receipt, less than 70% adherence, and 70% or greater adherence. We selected 70% or greater as estimation of a fairly high degree of adherence in the absence of a widely recognized metric for immunoprophylaxis. E1 We classified percentage adherence into 3 levels, including no receipt, because although patients with and without receipt of immunoprophylaxis varied regarding medical complexity, limiting the analyses to only those with receipt did not change the results (data not shown). For PS-matched analyses, the subset of children with extremes of RSV immunoprophylaxis adherence was included. E15 Covariates in the multivariable models included infant sex, EGA, EGA plus birth hospital LOS, birth weight, bronchiolitis diagnosis, season of birth (RSV season: October-March vs non-RSV season: AprilSeptember), birth year, number of living siblings, maternal race, age, education, gravidity, smoking during pregnancy, and site. For TennCare, when birth hospital LOS was missing, it was imputed, as previously described.
E1
Each regression adjustment method (multivariable logistic regression and PS-adjusted and PS-matched models) was conducted in the all RSV immunoprophylaxis-eligible cohort and in each subgroup based on eligibility criteria (CLD, Prematurity <29, Prematurity <32, and Other Eligible). Adjusted ORs for asthma were determined by means of adherence to AAP RSV immunoprophylaxis recommendations categorized as no receipt, less than 70% adherence, or 70% or greater adherence in the conventional multivariable and PS-adjusted models. Model fits (for conventional logistic regression methods) were assessed by using the goodness-of-fit test (Cessie-van Houwelingen-Copas-Hosmer), and there was no statistically significant evidence of lack of fit in our logistic regression models.
PS adjustment models. PS was derived by using a proportional odds ordinal logistic regression model for treatment (RSV immunoprophylaxis) with 3 level categories (no receipt, <70% adherence, and > _70% adherence) and included as a covariate in the PS adjustment model. E16 After derivation of the PS, in adjustment models restricted cubic splines were used to allow for nonlinear adjustment between PS and outcome.
PS-matched treatment groups. We derived the PS for matched analyses using binary logistic regression with high and low ends of receipt, including 70% or greater and greater than 0% to 20% or less adherence. E1 The PS-matched model included 1:1 matching, with replacement E15-E17 based on the PS to assess the association of percentage adherence with recommended number of doses of RSV immunoprophylaxis in infancy and subsequent asthma. In the matched analysis conditional logistic regression and robust sandwich error estimates were used to account for the clustered data. The significance level for all analyses was a P value of less than .05.
To assess the effect of missing covariate data, we conducted conventional multivariable adjustment models by using multiple imputation of missing variables. Because the results of these analyses remained unchanged, we present the complete case analyses. Overall, less than 2% of children were excluded from multivariable analyses because of missing/unknown data. Analyses were conducted with SAS (version 9.1, SAS Institute) and R (version 3.0.1; http://www.r-project.org) software. E18 FIG E1. Among infants with nonzero adherence, the adjusted association of adherence (black lines) with childhood asthma outcome (predicted probability) was evaluated by using restricted cubic splines (2 df with 3 knots) in multivariable logistic regression for combined and risk eligibility groups. Adherence of 1 indicates 100% adherence, and x-axes were trimmed to about 200% adherence. The histograms in red on the top axis show adherence distribution.
